Related Experiment Video

Updated: Apr 27, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.3K

Is the UK NICE "reference case" influencing the practice of pediatric quality-adjusted life-year measurement within

Nick Adlard1, Philip Kinghorn1, Emma Frew1

  • 1Health Economics Unit, School of Health & Population Sciences, University of Birmingham, Birmingham, Edgbaston, UK.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|June 28, 2014
PubMed

Insights

Pediatric cost-utility analyses in the UK often deviate from National Institute for Health and Care Excellence (NICE) guidelines. Studies frequently use adult measures for health outcomes instead of child-specific instruments, impacting quality-adjusted life-year assessments.

Area of Science:

  • Health Economics
  • Pediatric Health Services Research

Background:

  • The practice of conducting cost-utility analyses (CUAs) in pediatric populations within the UK has evolved over time.
  • Assessing and valuing health-related outcomes in these analyses is a critical component.

Purpose of the Study:

  • To systematically review the evolution of UK pediatric CUAs, focusing on outcome assessment and valuation.
  • To compare current methods with the National Institute for Health and Care Excellence (NICE) reference case guidelines.

Main Methods:

  • Systematic review of studies published between May 2004 and April 2012 (MEDLINE, Embase, Cochrane) and May 2004 to December 2010 (Paediatric Economic Database Evaluation).
  • Screening of identified studies by three independent reviewers.

Main Results:

  • Forty-three studies were identified; 11 used primary research for utility values.
  • Significant discrepancies exist between methods used for outcome measurement/valuation and NICE recommendations.
  • Most studies employed adult measures for health outcomes, contrary to NICE guidance for child-specific instruments.

Conclusions:

  • Future pediatric CUAs should clearly define age ranges and perspectives for costs and effects.
  • Increased research funding is recommended for primary studies measuring utilities specifically in children.
  • Addressing variability in quality-adjusted life-year measurement is crucial for aligning with NICE guidelines.
Abstract

Keywords:
economic evaluationhealth-related quality of lifeliterature reviewpediatricutility

More Related Videos

Assessment of Child Anthropometry in a Large Epidemiologic Study09:36

Assessment of Child Anthropometry in a Large Epidemiologic Study

Published on: February 2, 2017

26.7K

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
Bias in Epidemiological Studies01:29

Bias in Epidemiological Studies

Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:  
1.6K
Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.5K
Regression Toward the Mean01:52

Regression Toward the Mean

Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
6.3K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
405